April 26, 2017 / 2:11 PM / 4 months ago

BRIEF-ALNYLAM REPORTS FINAL 24-MONTH RESULTS FROM PHASE 2 OPEN-LABEL EXTENSION STUDY OF PATISIRAN

April 26 (Reuters) - Alnylam Pharmaceuticals Inc

* ALNYLAM REPORTS FINAL 24-MONTH RESULTS FROM PHASE 2 OPEN-LABEL EXTENSION STUDY OF PATISIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC IN DEVELOPMENT FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS

* REMAINS ON TRACK TO PRESENT TOP-LINE RESULTS FROM ITS ONGOING APOLLO PHASE 3 STUDY OF PATISIRAN IN MID-2017

* ALNYLAM PHARMA - RESULTS DEMONSTRATE THAT PATISIRAN HAS POTENTIAL TO HALT OR IMPROVE NEUROPATHY PROGRESSION ACROSS A BROAD RANGE OF NEUROLOGIC IMPAIRMENT

* ALNYLAM PHARMA - PHASE 2 OLE PATIENTS HAVE ROLLED OVER TO ONGOING, GLOBAL APOLLO-OLE TRIAL, PLAN TO PRESENT 36-MONTH DATA FROM COHORT OF PATIENTS IN LATE 2017

* ALNYLAM PHARMA - PATISIRAN FOUND TO BE WELL TOLERATED, WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS FOR UP TO 25 MONTHS OF TREATMENT OR DRUG-RELATED DISCONTINUATIONS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below